Intravitreal Triamcinolone Acetonide as Adjunctive Treatment with Systemic Therapy for Uveitic Macular Edema

Abstract

Intravitreal triamcinolone acetonide appears to be an effective supplementary tool in the management of CME refractory to systemic immunosuppressive therapy. Retreatment might be required in some and may be associated with elevated intraocular pressure and cataract.

Long-Term Outcome of an Intravitreal Dexamethasone Implant for the Treatment of Noninfectious Uveitic Macular Edema

“…Intravitreal triamcinolone acetonide has been shown to be effective for the control of CME; however, the effect duration, i.e. the resolution or improvement of macular edema, lasts on average 3 months and is commonly associated with local side effects such as increased intraocular pressure (IOP) and the development or progression of cataract [6,7,8,9,10,11,12]. …”

Uveitic macular edema

“…28 The efficacy duration may differ and a median time to recurrence is 5 months. 29,30 The fluocinolone acetonide implant (0.2 microg/day Iluvien) releases the drug through 36 months while 0.5 microg/day Retisert releases the drug through 30 months, release timing consistent with the clinical results timing on diabetic ME. 28 Regarding adverse events (AEs), corticosteroid-induced glaucoma is well-known.…”

Review and update of intraocular therapy in noninfectious uveitis

“…It also enabled the doses of oral corticosteroids and second-line immunosuppressive agents to be reduced or stopped [4]. IVTA has also been shown to be effective in eyes where CME persists after ocular inflammation has been effectively controlled, with response rates of up to 85% being reported [28][29][30][31][32][33].…”